A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase 3 Active not recruiting 700 enrolled Akero Therapeutics, Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.

Timeline

Start: 2023-11-10
Primary completion: 2026-03-03
Completion: 2026-06-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efruxifermin	Protein / enzyme biologic	50 mg	Subcutaneous

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Summary

Timeline

Drugs

Indications